Study Reveals Benefits of Drug for Overactive Bladder

Share this content:

A new phase 3 trial has found that mirabegron, a beta-3-adrenoceptor agonist, given once daily for 12 weeks reduced the frequency of incontinence episodes and number of daily urinations in adults with overactive bladder compared to with patients in a placebo group.

The researchers also found that the incidence of commonly experienced adverse events was similar in the mirabegron and placebo groups. John Schieszer has the story in today's Medical Minute.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters